

## Supplemental Online Content

Arkell TR, Downey LA, Hayley AC, Roth S. Assessment of medical cannabis and health-related quality of life. *JAMA Netw Open*. 2023;6(5):e2312522. doi:10.1001/jamanetworkopen.2023.12522

**eTable 1.** Data Availability on Quality of Life (SF-36) Measures by Follow-up

**eTable 2.** OLS Regression Results, Estimating General Health (Increasing From 0 to 100)

**eTable 3.** OLS Regression Results, Estimating Bodily Pain (Decreasing From 0 to 100)

**eTable 4.** OLS Regression Results, Estimating Physical Functioning (Increasing From 0 to 100)

**eTable 5.** OLS Regression Results, Estimating Role-Physical (Decreasing From 0 to 100)

**eTable 6.** OLS Regression Results, Estimating Mental Health (Increasing From 0 to 100)

**eTable 7.** OLS Regression Results, Estimating Role-Emotional (Decreasing From 0 to 100)

**eTable 8.** OLS Regression Results, Estimating Social Functioning (Increasing From 0 to 100)

**eTable 9.** OLS Regression Results, Estimating Vitality (Increasing From 0 to 100)

**eTable 10.** Reported Adverse Events Across Different Severity Levels

**eFigure.** Flow of Patients Through the Study of the Association of Medicinal Cannabis With Health-Related Quality of Life

This supplemental material has been provided by the authors to give readers additional information about their work.

**eTable 1.** Data availability on quality of life (SF-36) measures by follow-up.

Follow-up:	0 <sup>a</sup>	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
General health (% of sample)	3,096 (78.3)	328 (10.4)	405 (15.1)	717 (33.1)	616 (34.7)	545 (37.2)	516 (44.0)	384 (39.3)	347 (44.4)	257 (40.2)	224 (43.7)	167 (39.4)	148 (41.2)	127 (42.6)	109 (43.1)	84 (40.2)
Bodily pain (% of sample)	3,117 (78.8)	333 (10.5)	411 (15.3)	725 (33.5)	622 (35.1)	548 (37.4)	523 (44.5)	387 (39.6)	347 (44.4)	263 (41.1)	226 (44.1)	171 (40.3)	148 (41.2)	127 (42.6)	109 (43.1)	85 (40.7)
Physical functioning (% of sample)	3,124 (79.0)	336 (10.6)	412 (15.4)	724 (33.5)	628 (35.4)	550 (37.5)	525 (44.7)	389 (39.8)	347 (44.4)	263 (41.1)	226 (44.1)	175 (41.3)	148 (41.2)	129 (43.3)	108 (42.7)	85 (40.7)
Role-physical (% of sample)	3,105 (78.5)	334 (10.5)	413 (15.4)	723 (33.4)	627 (35.4)	549 (37.5)	525 (44.7)	386 (39.5)	346 (44.2)	262 (40.9)	227 (44.2)	173 (40.8)	148 (41.2)	128 (43.0)	109 (43.1)	84 (40.2)
Mental health (% of sample)	3,103 (78.4)	329 (10.4)	408 (15.2)	716 (33.1)	615 (34.7)	546 (37.3)	514 (43.8)	386 (39.5)	347 (44.4)	259 (40.5)	226 (44.1)	170 (40.1)	148 (41.2)	128 (43.0)	109 (43.1)	84 (40.2)
Role-emotional (% of sample)	3,108 (78.6)	336 (10.6)	414 (15.4)	726 (33.5)	625 (35.3)	549 (37.5)	525 (44.7)	387 (39.6)	347 (44.4)	262 (40.9)	227 (44.2)	173 (40.8)	148 (41.2)	128 (43.0)	109 (43.1)	85 (40.7)
Social functioning (% of sample)	3,081 (77.9)	319 (10.1)	387 (14.4)	697 (32.2)	609 (34.3)	531 (36.2)	501 (42.7)	375 (38.4)	335 (42.8)	250 (39.1)	221 (43.1)	163 (38.4)	145 (40.4)	125 (42.0)	107 (42.3)	81 (38.8)
Vitality (% of sample)	3,103 (78.4)	328 (10.4)	408 (15.2)	718 (33.2)	619 (34.9)	546 (37.3)	516 (44.0)	386 (39.5)	347 (44.4)	259 (40.5)	226 (44.1)	171 (40.3)	148 (41.2)	128 (43.0)	109 (43.1)	84 (40.2)
# of days elapsed <sup>b</sup>	0	49	86	130	177	221	268	318	363	413	452	492	537	566	602	630

Notes: <sup>a</sup>Corresponds to the initial assessment at baseline before commencing treatment with medicinal cannabis. <sup>b</sup>Indicates the average number of days that have passed since completing the baseline quality of life (SF-36) survey.

**eTable 2.** OLS regression results, estimating general health (increasing from 0 to 100).

	General effect			Balanced	CBD-dominant	THC-dominant
	(1)	(2)	(3)			
<i>Outcome: General health (mean at baseline = 40.22)</i>						
Treatment	5.94*** (0.60)	6.22*** (0.99)	8.42*** (0.86)	9.06*** (0.96)	8.67*** (0.91)	7.06*** (1.14)
Other				8.06*** (0.90)	8.12*** (0.92)	8.55*** (0.87)
Primary diagnosis categories <sup>a</sup>		Yes	Yes	Yes	Yes	Yes
# of comorbidities		-1.31*** (0.12)				
# of medications		-0.70*** (0.14)	-0.27 (0.14)	-0.27 (0.14)	-0.27 (0.14)	-0.27* (0.14)
Binary indicators for eight medication categories <sup>b</sup>		Yes	Yes	Yes	Yes	Yes
Age		0.15*** (0.03)	-1.25* (0.61)	-1.26* (0.61)	-1.25* (0.61)	-1.23* (0.61)
Female		-0.67 (0.92)				
Employed		5.02*** (1.08)				
Nonlinear treatment trend <sup>c</sup>		-3.44 (1.79)	-4.37*** (1.24)	-4.20*** (1.24)	-4.46*** (1.25)	-4.50*** (1.24)
Month- and year-fixed effects		Yes	Yes	Yes	Yes	Yes
Patient-fixed effects			Yes	Yes	Yes	Yes
# of patients	3,096	2,663	1,552	1,552	1,552	1,552
# of consults	16	16	16	16	16	16
<i>N</i>	8,070	7,016	6,597	6,597	6,597	6,597
<i>R</i> <sup>2</sup>	0.02	0.15	0.73	0.73	0.73	0.73
Effect sizes [Treatment]	[0.27***]	[0.28***]	[0.38***]	[0.41***]	[0.39***]	[0.32***]

Notes: Standard errors clustered at the patient level are displayed in parentheses. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

<sup>a</sup>Includes binary indicators for simple analgesics, opioids, antidepressants, benzodiazepines, GABA analogues, antipsychotics, compound analgesics, and other pain medications. <sup>b</sup>Includes fixed effects for the primary diagnosis categories of pain, psychiatric, neurological, and other. <sup>c</sup>Measured as the reciprocal of the number of follow-up consults since commencing treatment.

**eTable 3.** OLS regression results, estimating bodily pain (decreasing from 0 to 100).

	General effect			Balanced	CBD-dominant	THC-dominant
	(1)	(2)	(3)			
<i>Outcome: Bodily pain (mean at baseline = 29.85)</i>						
Treatment	13.12*** (0.63)	15.55*** (0.91)	17.34*** (0.98)	18.03*** (1.11)	17.65*** (1.04)	17.17*** (1.24)
Other				16.95*** (1.01)	16.97*** (1.04)	17.36*** (0.99)
Primary diagnosis categories <sup>a</sup>		Yes	Yes	Yes	Yes	Yes
# of comorbidities		-0.76*** (0.10)				
# of medications		0.16 (0.13)	-0.08 (0.16)	-0.07 (0.16)	-0.08 (0.16)	-0.08 (0.16)
Binary indicators for eight medication categories <sup>b</sup>		Yes	Yes	Yes	Yes	Yes
Age		0.00 (0.03)	-1.87** (0.70)	-1.87** (0.70)	-1.87** (0.70)	-1.87** (0.70)
Female		-1.66* (0.84)				
Employed		6.92*** (0.97)				
Nonlinear treatment trend <sup>c</sup>		-7.76*** (1.74)	-8.98*** (1.44)	-8.79*** (1.44)	-9.08*** (1.45)	-8.99*** (1.44)
Month- and year-fixed effects		Yes	Yes	Yes	Yes	Yes
Patient-fixed effects			Yes	Yes	Yes	Yes
# of patients	3,117	2,683	1,560	1,560	1,560	1,560
# of consults	16	16	16	16	16	16
<i>N</i>	8,142	7,069	6,618	6,618	6,618	6,618
<i>R</i> <sup>2</sup>	0.07	0.33	0.68	0.68	0.68	0.68
Effect sizes [Treatment]	[0.54***]	[0.64***]	[0.72***]	[0.75***]	[0.73***]	[0.71***]

Notes: Standard errors clustered at the patient level are displayed in parentheses. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

<sup>a</sup>Includes binary indicators for simple analgesics, opioids, antidepressants, benzodiazepines, GABA analogues, antipsychotics, compound analgesics, and other pain medications. <sup>b</sup>Includes fixed effects for the primary diagnosis categories of pain, psychiatric, neurological, and other. <sup>c</sup>Measured as the reciprocal of the number of follow-up consults since commencing treatment.

**eTable 4.** OLS regression results, estimating physical functioning (increasing from 0 to 100).

	General effect			Balanced	CBD- dominant	THC- dominant
	(1)	(2)	(3)	(4)	(5)	(6)
Treatment	5.29*** (0.78)	6.24*** (1.14)	6.60*** (1.04)	6.81*** (1.15)	6.68*** (1.09)	7.18*** (1.28)
Other				6.49*** (1.06)	6.51*** (1.10)	6.55*** (1.04)
Primary diagnosis categories <sup>a</sup>		Yes	Yes	Yes	Yes	Yes
# of comorbidities		-1.13*** (0.13)				
# of medications		-0.80*** (0.15)	0.24 (0.17)	0.24 (0.17)	0.24 (0.17)	0.24 (0.17)
Binary indicators for eight medication categories <sup>b</sup>		Yes	Yes	Yes	Yes	Yes
Age		-0.26*** (0.03)	-1.26 (0.73)	-1.26 (0.73)	-1.26 (0.73)	-1.27 (0.73)
Female		-3.17** (1.12)				
Employed		16.29*** (1.31)				
Nonlinear treatment trend <sup>c</sup>		-5.24** (2.09)	-2.80 (1.64)	-2.74 (1.65)	-2.83 (1.65)	-2.75 (1.64)
Month- and year-fixed effects		Yes	Yes	Yes	Yes	Yes
Patient-fixed effects			Yes	Yes	Yes	Yes
# of patients	3,124	2,690	1,563	1,563	1,563	1,563
# of consults	16	16	16	16	16	16
<i>N</i>	8,169	7,095	6,625	6,625	6,625	6,625
<i>R</i> <sup>2</sup>	0.01	0.33	0.79	0.79	0.79	0.79
Effect sizes [Treatment]	[0.17***]	[0.20***]	[0.21***]	[0.22***]	[0.22***]	[0.23***]

Notes: Standard errors clustered at the patient level are displayed in parentheses. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

<sup>a</sup>Includes binary indicators for simple analgesics, opioids, antidepressants, benzodiazepines, GABA analogues, antipsychotics, compound analgesics, and other pain medications. <sup>b</sup>Includes fixed effects for the primary diagnosis categories of pain, psychiatric, neurological, and other. <sup>c</sup>Measured as the reciprocal of the number of follow-up consults since commencing treatment.

**eTable 5.** OLS regression results, estimating role-physical (decreasing from 0 to 100).

	General effect			Balanced	CBD-dominant	THC-dominant
	(1)	(2)	(3)			
<i>Outcome: Role-physical (mean at baseline = 14.02)</i>						
Treatment	13.37*** (0.93)	14.52*** (1.46)	16.81*** (1.65)	16.73*** (1.75)	17.61*** (1.78)	16.29*** (2.20)
Other				16.86*** (1.75)	15.82*** (1.70)	16.86*** (1.64)
Primary diagnosis categories <sup>a</sup>		Yes	Yes	Yes	Yes	Yes
# of comorbidities		-1.10*** (0.14)				
# of medications		0.05 (0.16)	0.07 (0.26)	0.07 (0.26)	0.06 (0.26)	0.07 (0.26)
Binary indicators for eight medication categories <sup>b</sup>		Yes	Yes	Yes	Yes	Yes
Age		-0.02 (0.04)	-2.37 (1.25)	-2.37 (1.25)	-2.36 (1.25)	-2.36 (1.25)
Female		-0.82 (1.25)				
Employed		9.20*** (1.54)				
Nonlinear treatment trend <sup>c</sup>		-7.71** (2.68)	-9.37*** (2.59)	-9.40*** (2.62)	-9.64*** (2.62)	-9.42*** (2.59)
Month- and year-fixed effects		Yes	Yes	Yes	Yes	Yes
Patient-fixed effects			Yes	Yes	Yes	Yes
# of patients	3,105	2,670	1,562	1,562	1,562	1,562
# of consults	16	16	16	16	16	16
<i>N</i>	8,139	7,064	6,622	6,622	6,622	6,622
<i>R</i> <sup>2</sup>	0.03	0.16	0.49	0.49	0.49	0.49
Effect sizes [Treatment]	[0.46***]	[0.50***]	[0.58***]	[0.58***]	[0.61***]	[0.56***]

Notes: Standard errors clustered at the patient level are displayed in parentheses. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

<sup>a</sup>Includes binary indicators for simple analgesics, opioids, antidepressants, benzodiazepines, GABA analogues, antipsychotics, compound analgesics, and other pain medications. <sup>b</sup>Includes fixed effects for the primary diagnosis categories of pain, psychiatric, neurological, and other. <sup>c</sup>Measured as the reciprocal of the number of follow-up consults since commencing treatment.

**eTable 6.** OLS regression results, estimating mental health (increasing from 0 to 100).

	General effect			Balanced	CBD-dominant	THC-dominant
	(1)	(2)	(3)			
<i>Outcome: Mental health (mean at baseline = 54.06)</i>						
Treatment	9.35*** (0.56)	9.87*** (0.89)	11.00*** (0.86)	11.62*** (1.00)	11.07*** (0.90)	11.44*** (1.16)
Other				10.65*** (0.88)	10.91*** (0.94)	10.96*** (0.86)
Primary diagnosis categories <sup>a</sup>		Yes	Yes	Yes	Yes	Yes
# of comorbidities		-0.96*** (0.11)				
# of medications		0.50*** (0.12)	-0.10 (0.14)	-0.10 (0.14)	-0.10 (0.14)	-0.10 (0.14)
Binary indicators for eight medication categories <sup>b</sup>		Yes	Yes	Yes	Yes	Yes
Age		0.15*** (0.03)	-1.25* (0.63)	-1.26* (0.63)	-1.25* (0.63)	-1.26* (0.63)
Female		1.42 (0.85)				
Employed		5.31*** (0.88)				
Nonlinear treatment trend <sup>c</sup>		-3.13 (1.64)	-4.10** (1.27)	-3.93** (1.27)	-4.12** (1.27)	-4.05** (1.27)
Month- and year-fixed effects		Yes	Yes	Yes	Yes	Yes
Patient-fixed effects			Yes	Yes	Yes	Yes
# of patients	3,103	2,670	1,554	1,554	1,554	1,554
# of consults	16	16	16	16	16	16
<i>N</i>	8,088	7,030	6,602	6,602	6,602	6,602
<i>R</i> <sup>2</sup>	0.04	0.18	0.69	0.69	0.69	0.69
Effect sizes [Treatment]	[0.42***]	[0.44***]	[0.49***]	[0.52***]	[0.50***]	[0.51***]

Notes: Standard errors clustered at the patient level are displayed in parentheses. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

<sup>a</sup>Includes binary indicators for simple analgesics, opioids, antidepressants, benzodiazepines, GABA analogues, antipsychotics, compound analgesics, and other pain medications. <sup>b</sup>Includes fixed effects for the primary diagnosis categories of pain, psychiatric, neurological, and other. <sup>c</sup>Measured as the reciprocal of the number of follow-up consults since commencing treatment.

**eTable 7.** OLS regression results, estimating role-emotional (decreasing from 0 to 100).

	General effect			Balanced	CBD-dominant	THC-dominant
	(1)	(2)	(3)			
<i>Outcome: Role-emotional (mean at baseline = 28.37)</i>						
Treatment	16.17*** (1.05)	12.91*** (1.72)	14.19*** (2.13)	15.84*** (2.38)	13.61*** (2.24)	14.12*** (2.77)
Other				13.26*** (2.21)	14.90*** (2.27)	14.19*** (2.14)
Primary diagnosis categories <sup>a</sup>		Yes	Yes	Yes	Yes	Yes
# of comorbidities		-1.45*** (0.19)				
# of medications		0.15 (0.21)	-0.17 (0.38)	-0.17 (0.38)	-0.17 (0.38)	-0.17 (0.38)
Binary indicators for eight medication categories <sup>b</sup>		Yes	Yes	Yes	Yes	Yes
Age		0.02 (0.05)	-2.24 (1.59)	-2.26 (1.59)	-2.25 (1.59)	-2.24 (1.59)
Female		2.68 (1.48)				
Employed		9.85*** (1.70)				
Nonlinear treatment trend <sup>c</sup>		0.30 (3.43)	-1.12 (3.37)	-0.68 (3.37)	-0.93 (3.37)	-1.13 (3.38)
Month- and year-fixed effects		Yes	Yes	Yes	Yes	Yes
Patient-fixed effects			Yes	Yes	Yes	Yes
# of patients	3,108	2,673	1,562	1,562	1,562	1,562
# of consults	16	16	16	16	16	16
<i>N</i>	8,149	7,072	6,623	6,623	6,623	6,623
<i>R</i> <sup>2</sup>	0.04	0.09	0.41	0.41	0.41	0.41
Effect sizes [Treatment]	[0.43***]	[0.35***]	[0.38***]	[0.43***]	[0.37***]	[0.38***]

Notes: Standard errors clustered at the patient level are displayed in parentheses. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

<sup>a</sup>Includes binary indicators for simple analgesics, opioids, antidepressants, benzodiazepines, GABA analogues, antipsychotics, compound analgesics, and other pain medications. <sup>b</sup>Includes fixed effects for the primary diagnosis categories of pain, psychiatric, neurological, and other. <sup>c</sup>Measured as the reciprocal of the number of follow-up consults since commencing treatment.



**eTable 8.** OLS regression results, estimating social functioning (increasing from 0 to 100).

	General effect			Balanced	CBD- dominant	THC- dominant
	(1)	(2)	(3)	(4)	(5)	(6)
<i>Outcome: Social functioning (mean at baseline = 36.57)</i>						
Treatment	15.97*** (0.73)	17.03*** (1.18)	18.31*** (1.25)	20.19*** (1.40)	18.08*** (1.33)	17.10*** (1.62)
Other				17.24*** (1.30)	18.59*** (1.33)	18.43*** (1.26)
Primary diagnosis categories <sup>a</sup>		Yes	Yes	Yes	Yes	Yes
# of comorbidities		-1.03*** (0.13)				
# of medications		0.20 (0.16)	-0.24 (0.20)	-0.23 (0.20)	-0.23 (0.20)	-0.24 (0.20)
Binary indicators for eight medication categories <sup>b</sup>		Yes	Yes	Yes	Yes	Yes
Age		0.21*** (0.03)	-0.59 (0.89)	-0.61 (0.89)	-0.59 (0.89)	-0.56 (0.89)
Female		1.68 (1.07)				
Employed		10.99*** (1.15)				
Nonlinear treatment trend <sup>c</sup>		-6.08** (2.22)	-6.39*** (1.86)	-5.87** (1.86)	-6.31*** (1.87)	-6.51*** (1.87)
Month- and year-fixed effects		Yes	Yes	Yes	Yes	Yes
Patient-fixed effects			Yes	Yes	Yes	Yes
# of patients	3,081	2,647	1,535	1,535	1,535	1,535
# of consults	16	16	16	16	16	16
<i>N</i>	7,927	6,893	6,558	6,558	6,558	6,558
<i>R</i> <sup>2</sup>	0.07	0.18	0.61	0.61	0.61	0.61
Effect sizes [Treatment]	[0.60***]	[0.64***]	[0.68***]	[0.75***]	[0.67***]	[0.64***]

Notes: Standard errors clustered at the patient level are displayed in parentheses. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

<sup>a</sup>Includes binary indicators for simple analgesics, opioids, antidepressants, benzodiazepines, GABA analogues, antipsychotics, compound analgesics, and other pain medications. <sup>b</sup>Includes fixed effects for the primary diagnosis categories of pain, psychiatric, neurological, and other. <sup>c</sup>Measured as the reciprocal of the number of follow-up consults since commencing treatment.

**eTable 9.** OLS regression results, estimating vitality (increasing from 0 to 100).

<i>Outcome: Vitality (mean at baseline = 30.19)</i>						
	General effect			Balanced	CBD- dominant	THC- dominant
	(1)	(2)	(3)	(4)	(5)	(6)
Treatment	10.41*** (0.58)	11.85*** (0.99)	12.91*** (0.96)	13.66*** (1.11)	13.08*** (1.00)	12.52*** (1.20)
Other				12.48*** (0.97)	12.69*** (1.04)	12.94*** (0.97)
Primary diagnosis categories <sup>a</sup>		Yes	Yes	Yes	Yes	Yes
# of comorbidities		-1.01*** (0.10)				
# of medications		0.07 (0.13)	-0.09 (0.16)	-0.09 (0.16)	-0.09 (0.16)	-0.09 (0.16)
Binary indicators for eight medication categories <sup>b</sup>		Yes	Yes	Yes	Yes	Yes
Age		0.04 (0.03)	-0.90 (0.66)	-0.90 (0.66)	-0.89 (0.66)	-0.89 (0.66)
Female		-3.10*** (0.87)				
Employed		2.73** (1.01)				
Nonlinear treatment trend <sup>c</sup>		-6.65*** (1.81)	-6.46*** (1.39)	-6.26*** (1.38)	-6.52*** (1.39)	-6.50*** (1.39)
Month- and year-fixed effects		Yes	Yes	Yes	Yes	Yes
Patient-fixed effects			Yes	Yes	Yes	Yes
# of patients	3,103	2,668	1,554	1,554	1,554	1,554
# of consults	16	16	16	16	16	16
<i>N</i>	8,096	7,031	6,601	6,601	6,601	6,601
<i>R</i> <sup>2</sup>	0.05	0.14	0.63	0.63	0.63	0.63
Effect sizes [Treatment]	[0.50***]	[0.57***]	[0.62***]	[0.66***]	[0.63***]	[0.60***]

Notes: Standard errors clustered at the patient level are displayed in parentheses. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

<sup>a</sup>Includes binary indicators for simple analgesics, opioids, antidepressants, benzodiazepines, GABA analogues, antipsychotics, compound analgesics, and other pain medications. <sup>b</sup>Includes fixed effects for the primary diagnosis categories of pain, psychiatric, neurological, and other. <sup>c</sup>Measured as the reciprocal of the number of follow-up consults since commencing treatment.

**eTable 10.** Reported adverse events across different severity levels.

Adverse Event	Severity						Total	
	Mild	Moderate	Severe	Serious	Unspecified			
	<i>N</i>	<i>N</i>	<i>N</i>	<i>N</i>	<i>N</i>	<i>N</i>	(%)	
Sedation/sleepiness	288	116	7	0	0	411	(13.1)	
Dry mouth	284	74	1	0	0	359	(11.4)	
Lethargy/tiredness	153	75	4	0	0	232	(7.4)	
Dizziness	150	70	4	0	0	224	(7.1)	
Concentration difficulty	138	59	3	0	0	200	(6.4)	
Nausea	115	74	10	0	0	199	(6.3)	
Diarrhoea/loose stools	105	40	8	0	2	155	(4.9)	
Feeling high	105	42	1	0	0	148	(4.7)	
Increased appetite	91	27	0	0	0	118	(3.7)	
Headache	59	34	6	0	0	100	(3.2)	
Anxiety/panic attack	31	47	6	0	0	84	(2.7)	
Vivid dreams	35	17	0	0	1	53	(1.7)	
Hallucination	12	27	5	1	0	45	(1.4)	
Impaired coordination	29	10	1	0	0	40	(1.3)	
Palpitations	23	8	1	0	0	32	(1.0)	
Other <sup>a</sup>	287	202	28	1	1	519	(16.5)	

*Notes:* <sup>a</sup>Includes abdominal pain, absence seizures, acid reflux, aggression, agitation/disorientation, alertness, allergic conjunctivitis, allergic reaction/hives, altered taste, amotivational, anger/stress, anosmia, apathy, arm pain, atrial fibrillation, auditory hallucination, bad taste in mouth, behavioural change, bleeding gums, bloating, blurred vision, bowel movement change, bradycardia, brain fog, bruxism, burning throat, burping, butterflies in the stomach, chest pain, chills/shivers, clumsiness, cognitive impairment, collapsing, confusion, constipation, cough, decreased appetite, delirium, depression, drug interaction, dry eyes, dry skin, dysphagia, dysphoria, dysuria, edema, elevated liver function tests, emotional fragility, epigastric pain, erectile dysfunction, euphoria, fecal incontinence, feeling blunted, feeling drunk, feeling flat, feeling stoned, feeling unbalanced, feeling warm, fever, flatulence, foot numbness, funny turn, gelastic seizures, globus pharyngeus, goosebumps, hangover, hay fever, head banging, heartburn, heavy legs, hiccups, high blood pressure, hot flashes, hyperactivity, hyperacusis, hyponatraemia, hyponatremia, impaired movement, increased body pain, increased seizures, indigestion, insomnia, intoxication, intrusive thoughts, irritability, itchy skin, jittery, lack of control, lack of motivation, leg pain, lightheadedness, low blood pressure, low mood, mania, memory loss, metallic smell on body, metallic taste, mouth ulcers, muscle rigidity, muscle twitch, muscle twitch/tremors, nightmares, ocular hypertension, out-of-body experience, overthinking, paradoxical reaction, paranoia, phlegm, pressure in the head, pseudobulbar affect, psychogenic nonepileptic seizures, racing thoughts, restless arms, salty taste in mouth, seizure, shakes/tremors, shortness of breath, sinus pain, skin rash, sleeping difficulty, slurred speech, sore throat, sweating, swollen lips, tachycardia, throat irritation, tics, tingling tongue, tinnitus, ulcerative colitis, unsteadiness, urinary incontinence, use disorder/dependency, vertigo, voice change, vomiting, wakefulness, weakness, weight change, wheeze.

**eFigure.** Flow of patients through the study of the association of medicinal cannabis with health-related quality of life.

